SNX Form 4: CFO Witt Marshall Exercises Options and Sells 862 Shares
Rhea-AI Filing Summary
TD SYNNEX CFO Witt Marshall reported transactions on 08/11/2025 showing both an acquisition and a sale of 862 common shares. The filing records an acquisition at a per-share price of $57.34 and a contemporaneous sale at $146.39, leaving the reporting person with 49,777 shares beneficially owned after the sale (the filing also shows 50,639 shares following the acquisition prior to the sale). The filing discloses ownership of 9,471 employee stock options following the reported transactions and notes that the sales were made pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025.
The Form 4 includes an employee stock option entry with a conversion/exercise price of $57.34 for 862 underlying shares and describes the option vesting schedule. The report is signed on behalf of the reporting person by an attorney-in-fact on 08/12/2025.
Positive
- Sale executed under a Rule 10b5-1 plan, indicating transactions were pre-arranged (adopted May 12, 2025)
- Complete disclosure of share counts, prices, option holdings, and vesting schedule in the Form 4
Negative
- Net decrease in direct beneficial ownership of 862 shares (from 50,639 to 49,777) following the transactions
Insights
TL;DR: Routine option-related exercise and matched sale under a pre-established 10b5-1 plan; likely neutral to market.
The filing shows the CFO exercised or otherwise acquired 862 shares at $57.34 and sold 862 shares at $146.39 on 08/11/2025, with the sale executed under a Rule 10b5-1 plan adopted May 12, 2025. Such pre-arranged plans are commonly used to avoid timing concerns around material nonpublic information. The net effect reported is a reduction in direct beneficial ownership from 50,639 to 49,777 shares; derivative holdings of 9,471 options are also reported. These are routine insider transactions and, absent other material disclosures, present a neutral informational impact for investors.
TL;DR: Disclosure is transparent and notes use of a 10b5-1 plan; governance practices appear followed based on the filing.
The Form 4 documents both the exercise-related activity and a contemporaneous sale of the same number of shares and explicitly cites a Rule 10b5-1 plan adopted on May 12, 2025. The filing includes an explanation of the option vesting schedule and lists the signature of an attorney-in-fact. From a governance perspective, pre-established trading plans and clear reporting support compliance with insider trading rules. The filing contains no disclosures of unusual or unexplained transactions.